| Literature DB >> 24603478 |
Chong Yang1, He-Shui Wu1, Xing-Lin Chen2, Chun-You Wang1, Shan-Miao Gou1, Jun Xiao1, Zhi-Qiang He1, Qi-Jun Chen1, Yong-Feng Li1.
Abstract
BACKGROUND: The aim of this meta-analysis was to compare the long-term survival, mortality, morbidity and the operation-related events in patients with periampullary and pancreatic carcinoma undergoing pylorus-preserving pancreaticoduodenectomy (PPPD) and pylorus-resecting pancreaticoduodenectomy (PRPD).Entities:
Mesh:
Year: 2014 PMID: 24603478 PMCID: PMC3946060 DOI: 10.1371/journal.pone.0090316
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1A flow chart showing the progress of trials through the review.
Study characteristics of the included RCTs studies.
| Reference | Language | Sample Sizes | Patients Selection | Outcome | Critical Appraisal | ||
| PPPD | PRPD | Inclusion | Exclusion | ||||
|
| English | 64 | 66 | ♦Pancreatic head/periampullary carcinoma | ♦Infiltration of the peripyloric LN or stomach | ♦Survival | ♦No description of sample size calculation |
| ♦Undergoing PD | ♦Concomitant severe comorbidity | ♦Complications | ♦Proper reporting of sequential randomization | ||||
| ♦Combined liver resection | ♦DGE | ♦Adequate definition of outcome parameters | |||||
| ♦Proved mental illness | ♦Weight | ♦No description of allocation concealment/blinding | |||||
| ♦Without an informed consent | ♦QoL | ♦In-house sequential follow-up | |||||
| ♦Nutritional Status | ♦No loss to follow up | ||||||
| ♦Short follow-up period | |||||||
|
| English | 14 | 13 | ♦Suspected pancreatic/ periampullary carcinoma | ♦Previous gastric resection | ♦Survival | ♦No description of sample size calculation |
| ♦Distant metastases or locally unresectable tumors | ♦Complications | ♦Proper description of randomization process | |||||
| ♦Pylorus/stomach involved | ♦DGE | ♦ Proper definition of outcome parameters | |||||
| ♦ Refused to participate in the study | ♦ Pathological findings | ♦ No description of allocation concealment/blinding | |||||
| ♦ No loss to follow up | |||||||
| ♦ Short and long follow-up period | |||||||
|
| English | 14 | 19 | ♦ Pancreatic head/periampullary carcinoma | — | ♦ Survival | ♦ No description of sample size calculation |
| ♦ Undergoing PD | ♦ Complications | ♦ Inadequate description of randomization process | |||||
| ♦ DGE | ♦ Insufficient definition of outcome parameters | ||||||
| ♦ No description of allocation concealment/blinding | |||||||
| ♦Follow-up not specified | |||||||
| ♦Short- and long-term results inconsistent | |||||||
|
| English | 64 | 66 | ♦Suspected pancreatic/ periampullary carcinoma | ♦Previous gastric resection | ♦Survival | ♦Description of sample size calculation |
| ♦Considered resectable | ♦Complications | ♦Proper reporting of sequential randomization | |||||
| ♦Suitable for surgery | ♦DGE | ♦Adequate definition of outcome parameters | |||||
| ♦Weigt | ♦Reporting in accordance with CONSORT | ||||||
| ♦QoL | ♦Balanced study population | ||||||
| ♦Sequential, personal follow-up | |||||||
| ♦Allocation concealment unclear | |||||||
| ♦No specification of loss to follow-up | |||||||
|
| English | 87 | 83 | ♦Suspected pancreatic/ periampullary carcinoma | ♦Previous gastric resection | ♦Survival | ♦Description of sample size calculation |
| ♦Considered resectable | ♦Distant metastases | ♦Complications | ♦Adequate reporting of sequential randomization and allocation concealment | ||||
| ♦Pylorus/stomach involved | ♦DGE | ♦Adequate definition of outcome parameters | |||||
| ♦Positive peripyloric LN | ♦Weight | ♦Balanced study population | |||||
| ♦Multicenter approach | |||||||
| ♦In-house sequential follow-up | |||||||
| ♦No loss to follow up | |||||||
| ♦ITT analysis | |||||||
| ♦Short follow-up period | |||||||
|
| German | 24 | 24 | ♦Suspected pancreatic/periampullary carcinoma | ♦Infiltration of the pylorus or stomach | ♦Survival | ♦No description of sample size calculation |
| ♦Considered resectable | ♦Peritoneal carcinomatosis | ♦Complications | ♦Inadequate reporting on randomization process | ||||
| ♦Age >75 y | ♦DGE | ♦Insufficient definition of outcome parameters | |||||
| ♦Poor general health | ♦Weight | ♦Sequential, personal follow-up | |||||
| ♦QoL | ♦No description of allocation concealment/blinding | ||||||
| ♦Only R0 resections included/randomized (selection bias) | |||||||
| ♦Loss to follow-up 70.8% (PPW) and 58.3% (CW) | |||||||
|
| German | 23 | 21 | ♦Suspected periampullary carcinoma | — | ♦Complications | ♦No description of sample size calculation |
| ♦Stages cT1–4, cN0–1, cM0 | ♦DGE | ♦No description of randomization process | |||||
| ♦QoL | ♦Insufficient definition of outcome parameters | ||||||
| ♦No description of allocation concealment/blinding | |||||||
| ♦No specification of follow-up | |||||||
|
| German | 17 | 23 | ♦Suspected pancreatic/periampullary carcinoma | ♦Contraindication to surgery | ♦Survival | ♦No description of sample size calculation |
| ♦Considered resectable | ♦Metastases or advanced disease | ♦Complications | ♦Insufficient definition of outcome parameters | ||||
| ♦DGE | ♦Randomization process described | ||||||
| ♦Weight | ♦Sequential, personal, long follow-up period | ||||||
| ♦No description of allocation concealment/blinding | |||||||
Abbreviations and notes: —, not mentioned; DGE, delayed gastric empty; LN, lymph nodes; PD, pancreaticoduodenectomy; PPPD, pylorus-preserving pancreaticoduodenectomy; PRPD, pylorus-resection pancreaticoduodenectomy; QoL, quality of life; ITT, intention-to-treat analysis.
Egger's test and Begg's test of outcomes included in the meta-analysis.
| Mortality | Overall morbidity | Pancreatic fistula | Wound infection | Postoperative bleeding | Delayed gastric empty | Biliary leakage | Ascites | Gastroenterostomy leakage | |
| Egger's test | 0.787 | 0.280 | 0.425 | 0.575 | 0.523 | 0.003 | NA | 0.716 | NA |
| Begg's test | 0.497 | 1.0 | 0.573 | 0.624 | 1.0 | 0.039 | NA | 0.602 | NA |
Abbreviations and notes: NA, data not available.
Figure 2Forest plot of long-term survival.
The 95% confidence interval (CI) for the hazard ratio for each study is represented by a horizontal line and the point estimate is represented by a square. The size of the square corresponds to the weight of the study in the meta-analysis. Pooled treatment effect is shown as a diamond that spans the 95% CI. Data for a fix-effects model are shown as there was low statistical heterogeneity (I2 = 31%). df = degrees of freedom; IV = Inverse Variance; I2 = percentage of the total variation across studies due to heterogeneity; Z = test of overall treatment effect.
Figure 3Forest plot of mortality and morbidity.
The 95% confidence interval (CI) for the risk difference, risk ratio for each study is represented by a horizontal line and the point estimate is represented by a square. The size of the square corresponds to the weight of the study in the meta-analysis. The 95% CI for pooled estimates is represented by a diamond. df = degrees of freedom; MH = Mantel-Haenszel test; I2 = percentage of the total variation across studies due to heterogeneity; Z = test of overall treatment effect. A: mortality and morbidity for a fixed-effects model are shown as there were low statistical heterogeneity (I2<25%) (morbidity: including overall morbidity, pancreatic fistula, wound infection, postoperative bleeding, biliary leakage, ascites and gastroenterostomy leakage). B: Delayed gastric empty (DGE) for a random-effects model is shown as there was high statistical heterogeneity (I2 = 75%).
Figure 4Forest plot of operating time.
The 95% confidence interval (CI) for the hazard ratio for each study is represented by a horizontal line and the point estimate is represented by a square. The size of the square corresponds to the weight of the study in the meta-analysis. The 95% CI for pooled estimates is represented by a diamond. Data for a random-effects model is shown as there was high statistical heterogeneity (I2 = 83%). df = degrees of freedom; I2 = percentage of the total variation across studies due to heterogeneity; IV = Inverse Variance; Z = test of overall treatment effect.
Figure 5Forest plot of intraoperative blood loss.
The 95% confidence interval (CI) for the hazard ratio for each study is represented by a horizontal line and the point estimate is represented by a square. The size of the square corresponds to the weight of the study in the meta-analysis. The 95% CI for pooled estimates is represented by a diamond. Data for a random-effects model is shown as there was high statistical heterogeneity (I2 = 81%). df = degrees of freedom; I2 = percentage of the total variation across studies due to heterogeneity; IV = Inverse Variance; Z = test of overall treatment effect.
Figure 6Forest plot of red blood cell transfusion.
The 95% confidence interval (CI) for the hazard ratio for each study is represented by a horizontal line and the point estimate is represented by a square. The size of the square corresponds to the weight of the study in the meta-analysis. The 95% CI for pooled estimates is represented by a diamond. Data for a fix-effects model is shown as there was no statistical heterogeneity (I2 = 0%). df = degrees of freedom; I2 = percentage of the total variation across studies due to heterogeneity; IV = Inverse Variance; Z = test of overall treatment effect.
Figure 7Forest plot of hospital stay.
The 95% confidence interval (CI) for the hazard ratio for each study is represented by a horizontal line and the point estimate is represented by a square. The size of the square corresponds to the weight of the study in the meta-analysis. The 95% CI for pooled estimates is represented by a diamond. Data for a fix-effects model is shown as there was no statistical heterogeneity (I2 = 0%). df = degrees of freedom; I2 = percentage of the total variation across studies due to heterogeneity; IV = Inverse Variance; Z = test of overall treatment effect.